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Chromosomal translocations causing deregulated c-MYC expression are detectable in most Burkitt
lymphoma cases. However, little is known about the additional lesions necessary for lymphomagenesis.
Now, two independent studies, one of which was performed by Sander et al. in this issue of Cancer Cell,
identify constitutive PI3K signaling and CyclinD3mutations as cooperating lesions in both mice and humans.
The results have directly actionable therapeutic implications.Burkitt lymphoma (BL) arises from the
malignant transformation of germinal
center (GC) B cells and displays heteroge-
neous epidemiological features (Magrath,
2012). Although BL can occur sporadi-
cally in any population (sporadic BL
[sBL]), it is endemic in several equatorial
regions typically in Africa (endemic BL
[eBL]) and can also develop at significant
frequency in HIV-infected individuals
(hivBL) (Magrath, 2012). The etiology of
BL is associated with Epstein-Barr virus
(EBV) infection, and in the case of eBL,
with malaria, although the pathogenic
significance of these associations is still
unclear. For instance, EBV infection of
tumor cells is detectable in all eBL but is
detectable in only 30% of sBL and hivBL
cases. Moreover, most EBV transforming
genes are not expressed in the tumor cells
(Magrath, 2012). Intensive chemothera-
peutic regimens can cure the majority of
BL cases but cannot be used in devel-
oping countries due to their toxicity and
limited availability.
BL has garnered intense attention
because of its unusual epidemiological
distribution, which suggests complex
biological interactions with the host and
the environment (Magrath, 2012). Further-
more, it represents a landmark in tumor
biology research, being among the first
tumors for which a genetic alteration
of clear pathogenic significance was
discovered (Dalla-Favera et al., 1982;
Taub et al., 1982). In fact, chromosomal
translocations that involve the c-MYC
(MYC) proto-oncogene and the immu-
noglobulin loci and lead to deregulated
MYCexpression are detectable in virtually
all BL cases. Substantial evidence
indicates that MYC deregulation elicits
a range of cancer-causing effects
that include aberrant cell proliferation,metabolic reprogramming, and genomic
instability.
As for most cancer types, BL is likely to
develop through multiple genetic alter-
ations. Numerous studies have estab-
lished that MYC deregulation is not
sufficient for malignant transformation
but that additional lesions are required.
Yet, except for inactivation of p53, which
is detectable at variable frequencies in
the different BL subtypes (Gaidano et al.,
1991), little is known about the cooperat-
ing lesions that lead to BL development.
Now, however, two independent studies
(Sander et al., 2012 [in this issue ofCancer
Cell]; Schmitz et al., 2012), remarkably
complementary in their findings in mice
and humans, provide fundamental in-
sights into the pathogenesis of BL with
important and directly actionable thera-
peutic implications.
In this issue of Cancer Cell, researchers
in the laboratory of Klaus Rajewsky, in
collaboration with long-standing BL
experts in Europe, have identified novel
genetic lesions that cooperate with MYC
deregulation in generating BL in the
mouse (Sander et al., 2012). Based on
their previous work implicating the PI3K
pathway in the survival of mature B cells
(Srinivasan et al., 2009), Sander et al.
(2012) engineered mice expressing
deregulated MYC and constitutively-
active PI3K specifically in GC B cells, the
putative BL cell of origin. These mice
develop lymphoid malignancies strikingly
similar to human BL, indicating that PI3K
signaling can cooperate with MYC in the
development of BL. Compared with pre-
vious attempts to model human BL in
mice, the present one stands out for
its faithful recapitulation of BL in terms
of the activating pathways commonly
deregulated in this lymphoma, the siteCancer Cell 22of activation of these lesions (GC), and
the resulting tumor phenotype, which
displays all the characteristics of human
BL in terms of histology, cell surface
markers, expression of key transcription
factors, and immunological history
(Sander et al., 2012). Furthermore, co-
activation of MYC-PI3K often selects for
stabilizing mutations in cyclin D3, a key
regulator of cell cycle progression in
GC B cells (Peled et al., 2010). Impor-
tantly, similar mutations are reported in
a small survey of human BL, further con-
firming this mouse model as an accurate
phenocopy of human BL.
While the synergy between PI3K
signaling and MYC deregulation was sus-
pected based on normal B cell biology
(Kumar et al., 2006) and confirmed by
the phenotype of the new BL mouse
model, it remained unclear whether and
how the PI3K pathway contributes to
human BL. However, an independent
team led by Louis Staudt has now
resolved this issue and determined the
essential regulatory pathways that coop-
erate with MYC in BL pathogenesis
(Schmitz et al., 2012). By comprehensive
high-throughput RNA sequencing, they
identified a cadre of somatic coding
mutations in a large panel of BL cases
and then examined which of the mutated
genes/pathways was required to maintain
the BL phenotype. Remarkably, they
found that 70% of sBL display constitu-
tive activation of PI3K signaling caused
by mutations that either deregulate the
activity of the transcription factor TCF3
(E2A) or inactivate its negative regulator
ID3. The E2A/PI3K association in BL is
especially intriguing in light of recent
reports that this ‘‘module’’ has essential
functions in B cell fate and GC biology
(Kwon et al., 2008; Lin et al., 2010)., August 14, 2012 ª2012 Elsevier Inc. 141
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model above, a sizable fraction of human
BLs carried somatic mutations that
increase the stability of the E2A direct
target cyclin D3, probably driving cell
cycle progression. Pharmacological or
genetic inactivation of either PI3K sig-
naling or cyclin D3 function is toxic to BL
cells, indicating that these lesions are
required for tumor cell viability (Schmitz
et al., 2012). Overall, these results
demonstrate that the synergy between
deregulated MYC, PI3K and cyclin D3
experimentally observed in mice is a
naturally occurring pathway of BL lym-
phomagenesis in humans.
These new results raise a number of
intriguing questions and opportunities.
The transcriptome analysis of human BL
samples clearly indicate that a substantial
number of additional, recurrent, genetic
lesions of potential functional significance
are present in the coding genome of
human BL (Schmitz et al., 2012). No
doubt, additional analyses will be neces-
sary to ascertain which of these are more
relevant and/or required for full transfor-
mation. Given its remarkable mechanistic
similarity to human BL, the new mouse
model (Sander et al., 2012) should facili-
tate a systematic evaluation of these
lesions in BL development. In addition,
the initial analysis of human BL suggests
that the eBL subtype may carry at least
partially distinct lesions from sBL and
hivBL (e.g., a much lower frequency of cy-
clin D3 mutation). Although this observa-
tion is still preliminary due to the limited
number of eBL cases examined, it would
be consistent with the distinctive features142 Cancer Cell 22, August 14, 2012 ª2012 Eof eBL, including different chromosomal
breakpoints and a much higher frequency
of EBV infection of tumor cells. As such,
eBL may arise from pathogenic pathways
that are partially distinct from those
driving sBL and hivBL. Finally, both the
mouse and human tumors conclusively
show that BL is a genetically distinct entity
from other aggressive B cell lymphomas,
especially diffuse large B cell lymphoma.
These findings may therefore help in
their differential diagnosis in cases in
which the histologic pattern is not clearly
discriminating.
Despite more than three decades of
research, no effective drugs have yet
been developed to counter the oncogenic
consequences of MYC deregulation.
Thus, a particularly welcome outcome of
the new studies is their identification of
feasible targets for BL therapy. Indeed,
several approved drugs are already
available to either inactivate PI3K sig-
naling or cyclin D3 function, and prelimi-
nary results show that some of these are
active against BL. If validated in appro-
priate clinical trials, these drugs would
be far less toxic than currently available
chemotherapeutic regimens for BL. If
confirmed, these therapeutic develop-
ments could improve the already high
rate of cure of sBL. But more importantly,
they could change the still ominous
clinical history of eBL and hivBL in devel-
oping countries. The availability of a
faithful preclinical model of the disease,
clearly identified targets, and continu-
ously emerging new drugs suggest that
important changes in the diagnostic,
prognostic, and therapeutic managementlsevier Inc.of BL may appear in the textbooks in the
not so distant future.REFERENCES
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